Phosphate binder

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

Retrieved on: 
Thursday, January 5, 2023

LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrology 2023 meeting taking place in Bangkok, Thailand from March 30 – April 2, 2023.

Key Points: 
  • LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrology 2023 meeting taking place in Bangkok, Thailand from March 30 – April 2, 2023.
  • “With our recently announced successful bioequivalence study of Renazorb compared to Fosrenol®, we are looking forward to filing a New Drug Application with the U.S. Food and Drug Administration in mid-2023.
  • These data provide further evidence of the benefits of Renazorb as a powerful phosphate binder and highlight its enhanced product profile, which is expected to improve medication compliance and, thereby, improve outcomes and quality-of-life for patients.”
    “The exposure of these favorable data before an audience of international nephrologists should further expand awareness of the advantages of Renazorb to treat hyperphosphatemia and should bolster our positioning in any potential partnership or licensing discussions,” added Dr. Gupta.
  • Fosrenol is a registered trademark of Shire International Licensing BV.

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022

LOS ALTOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • The third quarter of 2022 and recent weeks have been particularly productive as we completed enrollment of our pivotal bioequivalence trial of RENAZORB, with topline results expected by year-end.
  • We remain on track to file a New Drug Application (NDA) in 2023, saidShalabh Gupta, M.D., Chief Executive Officer of Unicycive.
  • Dr. Gupta added, We were delighted to share favorable results from both our product candidates with the nephrology community at this years Kidney Week.
  • General and administrative expenses for the quarter ended September 30, 2022 were $1.7 million, compared with $0.9 million for the same quarter in 2021.

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022

Retrieved on: 
Wednesday, August 24, 2022

All abstracts for ASNs Kidney Week 2022 will be available via the ASN website ( www.asn-online.org/education/kidneyweek ) by October 14, 2022.

Key Points: 
  • All abstracts for ASNs Kidney Week 2022 will be available via the ASN website ( www.asn-online.org/education/kidneyweek ) by October 14, 2022.
  • Renazorb has been shown to offer unique phosphate binding characteristics, which have the potential to treat hyperphosphatemia in chronic kidney disease patients.
  • Unicycive is preparing a clinical bioequivalence study performed in healthy volunteers in order to submit a 505(b)(2) new drug application to the U.S. Food and Drug Administration.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .

Worldwide Late Stage Chronic Kidney Disease Drugs Industry to 2027 - Introduction of New Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 27, 2020

The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.

Key Points: 
  • The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.
  • Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others.
  • The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the late stage chronic kidney disease drugs market.

Fresenius Medical Care North America Presents New Insights Related to COVID-19 and Dialysis Innovations at Kidney Week 2020

Retrieved on: 
Thursday, October 22, 2020

These publications include new insights related to COVID-19, phosphate binders, a new dialysis system under development, and new software to attain relative blood volume.

Key Points: 
  • These publications include new insights related to COVID-19, phosphate binders, a new dialysis system under development, and new software to attain relative blood volume.
  • "These insights showcase the breadth and depth of our research team, highlighting the many ways that we are working to advance kidney care."
  • The annual symposium, reimagined virtually for 2020, is one of the most influential gatherings of kidney professionals in the world.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Global Phosphate Binder (Hyperphosphatemia) Market Analysis & Outlook 2019-2023 Featuring AMAG Pharmaceuticals, Vifor Pharma, Sanofi, and Akebia Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 5, 2019

The "Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.
  • Global Phosphate Binder Market: Industry Analysis & Outlook (2019-2023) provides extensive research and detailed analysis of the present market along with future outlook.
  • The global phosphate binder market is driven by an increasing aging population as well as the rising prevalence of chronic kidney diseases.
  • The report profiles the key players of the market including AMAG Pharmaceuticals, Inc., Vifor Pharma Ltd., Sanofi S.A., and Akebia Therapeutics Inc.

Global Hyperphosphatemia Drug Market Forecast 2019-2027

Retrieved on: 
Tuesday, November 27, 2018

The global hyperphosphatemia drugs market is expected to grow at a CAGR of 16.13% during the forecast period of 2019-2027.

Key Points: 
  • The global hyperphosphatemia drugs market is expected to grow at a CAGR of 16.13% during the forecast period of 2019-2027.
  • Of these, the Calcium-based phosphate binder's held the largest market share of xx% in 2018 and is expected to continue its dominance during the forecast period.The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients.
  • In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.
  • However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of xx% during the forecast period.